報價延遲最少15分鐘:2025/11/15 03:03 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.55 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.42/--
|
|
企業價值
2.44B
|
| 資產負債 |
|
每股賬面淨值
-11.45
|
| 現金流量 |
|
現金流量率
0.16
|
| 損益表 |
|
收益
1.12B
|
|
每股收益
19.04
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/11/15 03:03 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safetydevices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States. |
